Insider · CIK 0001752631
Meredith Manning
Files at SLNO (SOLENO THERAPEUTICS INC). First filing Mar 31, 2026, latest Mar 31, 2026.
In brief
Meredith Manning files SEC Form 4 as officer at SLNO (SOLENO THERAPEUTICS INC). Since Mar 31, 2026, Meredith Manning has reported 0 open-market buys worth $0 and 1 open-market sell worth $229k, the latest filed on Mar 31, 2026.
A track record needs three past buys with six months of prices behind them; Meredith Manning has 0, so none is measured yet.
The newest scored trade: sold $229k of SLNO on Mar 27, 2026, filed Mar 31, 2026, scored 41 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $229k.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | SOLENO THERAPEUTICS INC | $229k 7,522 shares | -10% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 27, 2025 | SLNO SOLENO THERAPEUTICS INC | 48,000 0.10% of outstanding | $2.4M | Mar 27, 2025 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | SLNO SOLENO THERAPEUTICS INC | DDisposition to issuer Common Stock | -64,507 | - | - | 0 | May 18, 2026 |
| May 18, 2026 | SLNO SOLENO THERAPEUTICS INC | DDisposition to issuer Employee stock option (right to buy)derivative | -91,000 | - | - | 0 | May 18, 2026 |
| May 18, 2026 | SLNO SOLENO THERAPEUTICS INC | DDisposition to issuer Employee Stock Option (Right to buy)derivative | -29,200 | - | - | 0 | May 18, 2026 |
| May 18, 2026 | SLNO SOLENO THERAPEUTICS INC | DDisposition to issuer Employee Stock Option (Right to buy)derivative | -32,800 | - | - | 0 | May 18, 2026 |
| Mar 27, 2026 | SLNO SOLENO THERAPEUTICS INC | SOpen-market sale Common Stock | -4,864 | $30.04 | $146k | 67,165 | Mar 31, 2026 |
| Mar 27, 2026 | SLNO SOLENO THERAPEUTICS INC | SOpen-market sale Common Stock | -2,100 | $31.04 | $65k | 65,065 | Mar 31, 2026 |
| Mar 27, 2026 | SLNO SOLENO THERAPEUTICS INC | SOpen-market sale Common Stock | -558 | $31.72 | $18k | 64,507 | Mar 31, 2026 |
| Jan 21, 2026 | SLNO SOLENO THERAPEUTICS INC | AGrant or award Common Stock | +28,600 | $0.00 | $0 | 72,029 | Jan 23, 2026 |
| Jan 21, 2026 | SLNO SOLENO THERAPEUTICS INC | AGrant or award Employee stock option (right to buy)derivative | +32,800 | $0.00 | $0 | 32,800 | Jan 23, 2026 |
| Dec 15, 2025 | SLNO SOLENO THERAPEUTICS INC | FTax withholding Common Stock | -1,922 | $49.95 | $96k | 43,429 | Dec 17, 2025 |
Questions about Meredith Manning
Answered from the filings on this page, as of the latest one.
Is Meredith Manning buying or selling?
In the last 12 months Meredith Manning reported 0 open-market buys worth $0 and 1 open-market sell worth $229k on SEC Form 4; the latest was sold $229k of SLNO on Mar 27, 2026. Grants, option exercises and tax withholding are not counted.
How did Meredith Manning's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Meredith Manning has 0.
Where does Meredith Manning file Form 4?
Meredith Manning has filed Form 4 at SLNO (SOLENO THERAPEUTICS INC) as Chief Commercial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.